Subsequent Events Through March 29, 2022 |
12 Months Ended |
|---|---|
Dec. 31, 2021 | |
| Subsequent Events [Abstract] | |
| Subsequent Events Through March 29, 2022 |
13. Subsequent Events
On January 6, 2022, the Company entered into a Master Services Agreement with Quotient Sciences Limited, a UK based company that provides drug development and analysis services, for the purpose of performing clinical research in support of UNI-494.
On February 9, 2022, the Company entered into a Master Services Agreement with CBCC Global Research Inc., a California based company that provides clinical trial and related service, for the purpose of performing clinical research in support of Renazorb. |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|